Chc 1030

More than 80'000 people are affected by epilepsy in Switzerland. Angelini Pharma has made a commitment to improving patients’ lives and easing seizure control. We aspire to do this by making innovative therapies available to more patients.


What is epilepsy?

Epilepsy is a serious, chronic and debilitating neurological disease affecting people of all ages. It is characterised by recurrent unprovoked seizures that result from a disruption in the normal balance of electrical signals in the brain. 1, 2

Epilepsy affects the lives of patients in many ways. From not being able to drive to physical, psychological, and social challenges – the condition can have an impact on self-esteem, family, relationships, leisure, work, and career prospects.

Isolated and stigmatised by society3,4 Limitations in education and work3,4 Excluded from social interactions and relationships3,4

The International League Against Epilepsy (ILAE) defines four types of epilepsy5:

  • Focal epilepsy is characterised by epileptic seizures that start in one hemisphere of the brain.
  • Generalised epilepsy is characterised by seizures that originate in both hemispheres of the brain.
  • Combined generalised and focal epilepsy is a combination of focal and generalised seizures.
  • If it is not possible to determine the origin of seizures in the brain, it is called unknown epilepsy.

Angelini Pharma is determined to contribute to more seizure control for epilepsy patients.

For more detailed information on epilepsy, please visit Harmonia Mentis - our knowledge hub and information center dedicated to epilepsy and brain health created with patients and caregivers in mind or Epi Suisse, the patient organisation for people with epilepsy and their relatives.

If you are a healthcare professional and would like to learn more, please refer to our HCP Portal. If you are a patient or caregiver or for general inquiries, please refer to Harmonia Mentis.



  1. Epilepsy: a public health imperative. Summary. Geneva: World Health Organization; 2019. Licence: CC BY-NC-SA 3.0 IGO.
  2. Scharfman HE. Curr Neurol Neurosci Rep. 2007;7(4):348–354.
  3. de Boer HM, et al. Epilepsy Behav. 2008;12(4):540–546.
  4. Laxer KD, et al. Epilepsy Behav. 2014;37:59–70.
  5. Scheffer IE, et al. Epilepsia. 2017;58(4):512–521.